|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Biosimilars Series: Strategic issues - Potential remains uncertain |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Octobre 2007 |
Taille du document : |
104 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 47 pages | Mai 2007 | Anglais
|
|
|
| Main
focus: |
generics,pharmaceutical,pharmaceuticals,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,germany,canada,france,united kingdom,italy,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmacogenomics
160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets
150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry.
Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics.
V |
953,48 €
|
| |
| |
05-001: Improving Sales Rep Performance: A Global Analysis
219 pages | Janvier 2005 |
This report is designed to offer insights on how sales executives can align their sales force organization, recruitment and training in a way that reflects the needs and expectations of scientific cus |
1 520,00 €
|
| |
| |
Bioinformatics
150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data.
Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Combinatorics
150 pages | Décembre 2000 |
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals sector, Combinatorics (also known as combinatorial chemistry) is an emerging platform technology that uses test t |
1 400,00 €
|
| |
| |
DNA Sequencing and PCR Markets
252 pages | Novembre 2004 |
The focus of this report is to describe the specific segment of the life sciences market called DNA sequencing.
This analysis includes all of the generally accepted DNA-oriented analytical activiti |
2 800,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications
183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
Biogenerics: Challenges and Promise
154 pages | Janvier 2005 |
Biogenerics: Challenges and Promise takes an insightful look at the burgeoning biogenerics industry and helps to clarify the complicated regulations that currently govern biogeneric development in bot |
799,20 €
|
| |
| |
Carbohydrate Therapeutics IRCD
pages | Juillet 2001 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Biosimilars Series: Strategic issues - Potential remains uncertain |
|
|
Introduction
Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.
Scope
In-depth analysis of factors influencing market uptake of biosimilarsAnalysis of the pricing and reimbursement environment for biosimilarsDetailed analysis of barriers to entry and strategies for success in the biosimilar marketOverview of strategies for originators' market share protection
Highlights
Lack of automatic substitution with biosimilars means that intense promotion strategies need to be employed. Market uptake of biosimilars is highly dependent on acceptance by all key stakeholders especially physicians. All stakeholders need to be informed about biosimilars and various channels can be used.
Payers' reaction to biosimilars is not known, but it is expected they will embrace them after a lag period. Standard incentives used to encourage generics use may not be applicable to biosimilars distributed in hospitals and alternative approaches need to be used.
Barriers to entry remain high: high development and marketing costs compounded with the need for specialist expertise favor big players with strong financial backing and experience in branded generics industry. However smaller specialist players are well positioned to enter this market through co-development and co-marketing agreements.
Reasons to Purchase
Identify key stakeholders than need to be targeted in order to achieve high uptake of biosimilarsUnderstand the pricing and reimbursement environment of biosimilars, barriers to entry and key strategies for success in the biosimilars marketGain insight into strategies employed by innovative pharmaceutical and biotechnology companies in order to maintain their market share
|
|
ABOUT DATAMONITOR 2
OVERVIEW 4
This product has been designed for delivery in a slide pack format (ppt). 4
Please select the slide pack option from the download menu at the side of the page 4
Introduction 4
Scope of this report 4
Research and analysis highlights 4
Key reasons to read this report 4
|
|
|
PPLSEN
|
|
|
|
|
